ID93/GLA-SE Vaccination + BCG Challenge

"ID93/GLA-SE is a protein-adjuvant vaccine which has been purposefully designed to elicit a diverse immune response against M.tb bacterial antigens, improve treatment outcomes and prevent TB disease in people already infected with M.tb.~ID93/GLA-SE will be administered intramuscularly."

"BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.~For the challenge, aerosol BCG will be administered via nebulizer."